Triple-negative breast cancer (TNBC) is associated with high recurrence rates, high
incidence of distant metastases, and poor overall survival (OS). Taxane and anthracycline …

Breast cancer is the most common malignancy and the second most common cause of
cancer-related mortality in women. Triple-negative breast cancers do not express estrogen …

The poor progress of immunotherapy on osteosarcoma patients requires deeper delineation
of immune tolerance mechanisms in the osteosarcoma microenvironment and a new …

Identification and selectivity of molecular targets with prolonged action for difficult-to-target
cancer such as triple-negative breast cancer (TNBC) represent a persisting challenge in the …

Background/Aim: There is a strong association between malignancy and histone
deacetylases (HDACs). Histone deacetylase inhibitors (HDACIs) are now being tested as …

Triple‐negative breast cancer (TNBC) is caused due to the lack of estrogen receptors (ER),
progesterone receptors (PR), and human epidermal growth factor 2 (HER2) expression …

Triple-negative breast cancer (TNBC) is the most aggressive kind of breast cancer known to
mankind. It is a heterogeneous disease that is formed due to the missing estrogen …

Background Breast cancer (BC) is the most common malignancy and the leading cause of
cancer-related death in women worldwide. Sirtuin inhibitors (SIRTi), belonging to the histone …

Background Breast cancer (BC) is the most prevalent cancer type and is the principal cause
of cancer-related death in women. Anti-programmed cell death protein 1/programmed cell …

Background Breast cancer (BC) is the most prevalent cancer type and is the principal cause
of cancer-related death in women. Anti-PD-1/PD-L1 immunotherapy has shown promising …